Epsilon M&A Deal Report - GES Group
Transaction Multiples for the Valuation of Private Companies
Altan Pharma / GES Group
No EMAT :
72544
Announced Date :
11/06/2015
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Altan Pharma
Target :
GES Group
Country :
Spain
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
Business Description :
The GES Group develops, manufactures and markets specialty injectable drugs for the hospital and healthcare provider market. > GES, headquartered in Spain, is comprised of 3 operating companies: GES...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
| Date | Acquirer | Target | Country | Multiples | See details |
| 16/06/2015 | Private Group led by HLD, UI Gestion and DV France | IP Santé Domicile (IPS) | France | * | 72339 |
| 10/12/2012 | Eczacıbaşı-Monrol Nükleer Ürünler San. ve Tic. A.S | Capintec | United States | ** | 72157 |
Source: Epsilon Research / EMAT
